# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expect...
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.
Results Intended to Support Filing for Potential Label Extension for Use in Adolescents The latest VLA1553-321 data confirmed t...
HC Wainwright & Co. analyst Edward White reiterates Valneva (NASDAQ:VALN) with a Buy and maintains $26 price target.
2024 financial guidance confirmed Expected total revenues between €170 million and €190 million, including: €160 million...
Net Profit of €58.9 million, reflecting PRV sale
The randomized, placebo-controlled, Phase 1 trial, VLA1601-102, is planned to enroll approximately 150 participants aged 18 to ...